Clinical trials: Allogeneic Transplantation
Venentoclax, Myeloid Malignancies
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) serves as a curative treatment modality for the vast majority of patients with hematological malignancies.
- Conditions
- Venentoclax, Myeloid Malignancies, Conditioning, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Trial name
- NCT07396480
- Testing
- Venetoclax in combination with fludarabine and melphalan, Fludarabine and Melphalan
- Where
- 18 sites in China
- Volunteers
- 186 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation
Early Clinical Study on the Use of Donor-derived EBV-specific T Cells for the Prevention of EBV Infection After Allogeneic Hematopoietic Stem Cell Transplantation
This study is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial. Subjects will be recipients of allogeneic hematopoietic stem cell transplantation, with a planned enrollment of 9 to 18 subjects…
- Trial name
- NCT07476014
- Testing
- JYEST Cell Injection Infusion
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation
Primary Objective: It is hypothesized that the efficacy of Sitagliptin would reduce the incidence of grade II-IV acute Graft Versus Host Disease (GVHD) by day +100 post-transplant in patients undergoing alternative donor (related…
- Trial name
- SHIELD (NCT05149365)
- Testing
- Sitagliptin + Standard Prophylaxis, Standard Prophylaxis
- Where
- China
- Volunteers
- 190 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
- Trial name
- ADAPT (NCT06028828)
- Testing
- Fludarabine, Melphalan, Total Body Irradiation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of California, Irvine
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation
Seventy-five percent of patients treated with hematopoietic stem cell transplants survive one-year post-transplantation. However, this intensive treatment is associated with prolonged hospitalizations and significant…
- Trial name
- PrepAllo (NCT07341698)
- Testing
- Resistance training, Nutritional Support, Usual care
- Where
- Denmark
- Volunteers
- 110 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Carbapenem-resistant Enterobacterales
Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients
The goal of this observational study is to characterize the clinical features of metallo-β-lactamase-producing carbapenem-resistant Enterobacterales (MBL-CRE) colonization and subsequent infection in patients after allogeneic…
- Trial name
- NCT07324291
- Volunteers
- 1,000 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Allogeneic Hematopoietic Cell Transplantation (HCT), AML (Acute Myeloid Leukemia)
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
This study is a Phase II clinical trial designed to evaluate the efficacy and safety of Chidamide as maintenance therapy in high-risk acute myeloid leukemia (AML) patients following stem cell transplantation.
- Trial name
- CM-AML-001 (NCT07304232)
- Testing
- Chidamide
- Where
- 5 sites in China
- Volunteers
- 134 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Quality of Life, Patient Reported Outcome (PRO)
Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy
3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients…
- Conditions
- Quality of Life, Patient Reported Outcome (PRO), Allogeneic Blood and Marrow Transplantation (BMT), CAR T Cell Therapy
- Trial name
- QOL-ONE PRO-CT (NCT07289087)
- Volunteers
- 162 people
- Sponsor
- Associazione Qol-one
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, CMV
VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol
The study is one of the researches carried out in the VIROMARKERS Project. The project VIROMARKERS is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194735.
- Trial name
- NCT07286461
- Testing
- letermovir prophylaxis
- Where
- Germany
- Volunteers
- 290 people
- Sponsor
- University of Rome Tor Vergata
Myeloablative Allogeneic Hematopoietic Cell Transplantation, Intraoral Photobiomodulation Therapy
Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT).
- Conditions
- Myeloablative Allogeneic Hematopoietic Cell Transplantation, Intraoral Photobiomodulation Therapy, Oral Mucositis, Mucosal Ulcer
- Trial name
- NCT05335434
- Testing
- THOR LX2.3 with LED Lollipop
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Allogeneic Transplantation
Improve Outcomes for Older Allogeneic Transplant Recipients
This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility.
- Trial name
- NCT05612789
- Testing
- Exercise Program (Cohort A Prehab), Exercise Program (Cohort B Rehab)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)
The purpose of this study is to confirm that invariant NKT lymphocytes (iNKT) reconstitution in recipient and in the graft content can predict the outcome of human allogeneic HSCT and to set up an algorithm for clinical practice…
- Trial name
- REG-Allo (NCT02194868)
- Testing
- Recipients, Donors
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematologic Malignancies, Hematologic Disorders
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
This study reviews patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Some patients develop donor-specific antibodies (DSA), which can block engraftment and cause transplant failure.
- Conditions
- Hematologic Malignancies, Hematologic Disorders, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Graft Failure
- Trial name
- PAIA-Haplo (NCT07200583)
- Testing
- Protein A immunoadsorption, Rituximab (optional, in some patients), Bortezomib (optional, in some patients)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ting YANG
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT)
Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation
This study aims to evaluate the clinical performance of a novel microRNA-based detection platform, SE-SPTM-PCR, for identifying cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), CMV Reactivation, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Trial name
- SESPTM-CMV (NCT07181330)
- Testing
- SE-SPTM-PCR microRNA assay
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ting YANG
Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Virtual Reality Intervention for Symptom Management in Stem Cell Transplantation
The goal of this clinical trial is to evaluate whether a virtual reality (VR) intervention based on the Symptom Management Model can reduce physical and psychosocial symptoms during hematopoietic stem cell transplantation (HSCT)…
- Conditions
- Cancer and / or Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Nursing Interventions, Symptom Management
- Trial name
- NCT07145359
- Testing
- Virtual Reality Intervention
- Volunteers
- 30 people
- Sponsor
- Halic University
Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation
CIBMTR Research Database
The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies.
- Conditions
- Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Solid Tumors, Blood Cancers
- Trial name
- NCT01166009
- Where
- 2 sites in United States
- Volunteers
- 99,999,999 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
This study aims to explore the safety and efficacy of selinexor combined with azacitidine for maintenance therapy in TP53 mutant AML/MDS patients following transplantation.
- Trial name
- NCT07094464
- Testing
- Maintenance Therapy with Selinexor and Azacitidine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Daihong Liu
Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy is a rapidly developing novel approach in adoptive immunotherapy for tumors in recent years.
- Conditions
- Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Chimeric Antigen Receptor T-cell
- Trial name
- NCT07034755
- Testing
- autologous hematopoietic stem cell transplantation (ASCT) followed by CAR-T therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Immunoglobulin Prophylaxis, Cytomegalovirus Infections
Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region…
- Conditions
- Immunoglobulin Prophylaxis, Cytomegalovirus Infections, Allogeneic Hematopoietic Stem Cell Transplantation, Transplant-Related Disorder
- Trial name
- NCT07013370
- Testing
- Anti-CMV immunoglobulins [Megalotect (R)]
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Antonello Di Paolo, M.D., Ph.D.
Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases.
- Conditions
- Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia, Myelodysplastic Syndrome
- Trial name
- NCT06793410
- Testing
- Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9®
- Where
- 5 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Vastra Gotaland Region